PANTHERx®’s Leaders Present An American Journal of Managed Care® (AJMC) Webinar: The Clinical and Managed Care Implications of X-Linked Hypophosphatemia

PANTHERx® Specialty Pharmacy’s Chairman & CEO, Dr. Gordon J. Vanscoy, and PANTHERx®’s Manager of Clinical Programs, Dr. Christa Eans, will lead a Live CE Webinar as part of the American Journal of Managed Care® (AJMC) and the Pharmacy Times Continuing Education™. The webinar, titled, The Clinical and Managed Care Implications of X-Linked Hypophosphatemia will be offered free of charge at 6:00PM and 8:00PM ET on November 19, 2018 (today).

This webinar will explore the most common form of heritable rickets, X-linked hypophosphatemia (XLH), which is considered a rare disease in the United States. The main physiologic defect in XLH is impaired proximal renal tubular reabsorption of phosphate, which is crucial to healthy growth and development, bone formation, acid-base regulation, and cellular metabolism. Skeletal manifestations in adults and children are debilitating and significantly impact quality of life. Breakthrough therapies have emerged to improve the efficacy and tolerability that current treatments severely lack.

Experts in the field of rare and precision medicine, Dr. Vanscoy and Dr. Eans will provide an overview of the pathophysiology and clinical presentation of XLH, current and emerging treatment options, and managed care implications. This webinar will prove to be not only enlightening, but inspiring for those in, or wishing to learn more about, the challenges and implications of the specialty pharmacy industry.

To participate in this webinar, please go to: https://www.pharmacytimes.org/live/ajmc-webinar-implications-of-x-linked-hypophosphatemia?utm_medium=email&utm_campaign=PTCE%20X-Linked%20Live%20Webinar%2010-22-18&utm_content=PTCE%20X-Linked%20Live%20Webinar%2010-22-18+CID_7938b89f3563b7f57b09bd041e4034d8&utm_source=CM%20PTCE

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-18-185-L01-P. The activity is available for CE credit on November 19, 2018.

About PANTHERx Specialty Pharmacy
PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, is the industry leading, independent national specialty pharmacy headquartered in Pittsburgh, Pennsylvania. PANTHERx® Specialty’s mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Every day we create ways to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care®, by developing focused solutions, bold innovations, and novel clinical services associated with the life-transforming therapies that we deliver.

PANTHERx® was awarded 2018 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy as well as the American Pharmacy Purchasing Alliance. Zitter Health Insights awarded PANTHERx® the Specialty Pharmacy Patient Choice Award winner for both 2017 and 2018. Additionally, PANTHERx® was ranked #49 in the 2018 Inc. 5000 List of Fastest Growing Companies in the nation (top 100 for the last three years) and a Best Place to Work in Healthcare by Modern Healthcare magazine for 2018.

Comments are closed.